To review corticosteroid strategies for managing diabetic macular edema (DME), focusing on patient selection, dosing, safety, and integration with anti-VEGF therapy, highlighting their role in enhancing treatment outcomes.
Approach:
Key Findings:
Corticosteroids target multiple inflammatory pathways in DME, addressing issues not fully managed by anti-VEGF agents, which may lead to improved visual outcomes.
Intravitreal corticosteroids can improve patient adherence due to their longer duration of action, reducing the frequency of injections.
Emerging OCT biomarkers can help predict responses to steroid therapy, allowing for more tailored treatment approaches.
Interpretation:
Corticosteroids are a valuable addition to DME management, particularly for patients with chronic or refractory conditions, due to their broader anti-inflammatory effects that can lead to better visual and anatomical outcomes.
Limitations:
Potential adverse effects such as increased intraocular pressure and cataract formation, necessitating careful monitoring.
Need for careful patient selection to optimize outcomes, particularly in high-risk populations.
Conclusion:
Incorporating corticosteroids into DME treatment strategies can enhance patient outcomes, especially when tailored to individual patient needs and disease characteristics, emphasizing the importance of personalized treatment plans.
